肿瘤突变负荷：为何它仍是一个存在争议的非特异性免疫治疗生物标志物？
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?
作者信息
Mouawad Antoine, Boutros Marc, Chartouni Antoine, Attieh Fouad, Kourie Hampig Raphaël
机构信息
Faculty of Medicine, Université Saint-Joseph de Beyrouth, Beyrouth, Lebanon.
Department of Hematology-Oncology, Université Saint-Joseph de Beyrouth, Beyrouth, Lebanon.
出版信息
Future Oncol. 2025 Feb;21(4):493-499. doi: 10.1080/14796694.2024.2444862. Epub 2024 Dec 23.
Abstract
For the past few years, researchers and oncologists have been pushing to find biomarkers that would help predict which treatment option would best work on a patient. Tumor Mutational Burden (TMB) is one of the latest biomarkers that is being studied and considered as a promising agnostic immunotherapy biomarker. However, it still shows controversial results in studies due to the difficulty in finding solid comparable results. This is a consequence of different cutoff definitions among many cancer types, age ranges, and the use of different sequencing assays, in addition to its association with other biomarkers such as PD-L1. Finally, the use of composite biomarkers to assess the genetic signature of a tumor might be the way forward to seriously use TMB as an agnostic biomarker.
摘要
在过去几年里，研究人员和肿瘤学家一直在努力寻找生物标志物，以帮助预测哪种治疗方案对患者最有效。肿瘤突变负荷（TMB）是正在研究的最新生物标志物之一，被认为是一种有前景的非特异性免疫治疗生物标志物。然而，由于难以找到可靠的可比结果，它在研究中仍显示出有争议的结果。这是多种癌症类型、年龄范围之间不同的临界值定义，以及使用不同的测序检测方法的结果，此外还因其与其他生物标志物如程序性死亡受体配体1（PD-L1）有关。最后，使用复合生物标志物来评估肿瘤的基因特征可能是将TMB作为一种非特异性生物标志物加以认真应用的前进方向。
相似文献
1
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?肿瘤突变负荷：为何它仍是一个存在争议的非特异性免疫治疗生物标志物？
Future Oncol. 2025 Feb;21(4):493-499. doi: 10.1080/14796694.2024.2444862. Epub 2024 Dec 23.
2
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.免疫检查点抑制剂联合治疗的益处及肿瘤突变负担在肝细胞癌中的预测作用：系统评价和荟萃分析。
Int Immunopharmacol. 2022 Nov;112:109244. doi: 10.1016/j.intimp.2022.109244. Epub 2022 Sep 18.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
High matrix metalloproteinase-2 expression predicts poor prognosis of colon adenocarcinoma and is associated with PD-L1 expression and lymphocyte infiltration.高基质金属蛋白酶-2表达预示着结肠腺癌的预后不良，并与程序性死亡受体配体1（PD-L1）表达及淋巴细胞浸润相关。
PeerJ. 2025 Jun 30;13:e19550. doi: 10.7717/peerj.19550. eCollection 2025.
5
Comprehensive analysis of single-cell and bulk RNA sequencing data reveals an EGFR signature for predicting immunotherapy response and prognosis in pan-cancer.单细胞和批量RNA测序数据的综合分析揭示了一种用于预测泛癌免疫治疗反应和预后的EGFR特征。
Front Immunol. 2025 Jun 12;16:1604394. doi: 10.3389/fimmu.2025.1604394. eCollection 2025.
6
Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy.在免疫治疗时代，探索肛管鳞状细胞癌免疫细胞预测生物标志物和可操作基因改变中的程序性死亡受体配体1（PD-L1）
ESMO Open. 2025 Jun;10(6):105315. doi: 10.1016/j.esmoop.2025.105315. Epub 2025 Jun 10.
7
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗：一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
8
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA？一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
9
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益：一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
10
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
引用本文的文献
1
: explore its carcinogenic potential and understand its role, prognostic value and biological significance in pan-cancer.探索其致癌潜力，并了解其在泛癌中的作用、预后价值和生物学意义。
Front Immunol. 2025 Aug 6;16:1619733. doi: 10.3389/fimmu.2025.1619733. eCollection 2025.
2
Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations.癌症研究中的网络药理学与人工智能：揭示RALGDS突变的生物标志物和治疗靶点
Sci Rep. 2025 Mar 29;15(1):10938. doi: 10.1038/s41598-025-91568-x.
本文引用的文献
1
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.评估接受免疫治疗的多种晚期癌症患者的肿瘤突变负担和结局。
JAMA Netw Open. 2023 May 1;6(5):e2311181. doi: 10.1001/jamanetworkopen.2023.11181.
2
Characterization of pancreatic cancer with ultra-low tumor mutational burden.超低肿瘤突变负担的胰腺癌特征。
Sci Rep. 2023 Mar 16;13(1):4359. doi: 10.1038/s41598-023-31579-8.
3
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.肿瘤突变负担作为度伐利尤单抗和/或替西木单抗治疗复发性或转移性头颈部鳞状细胞癌患者生存的预测指标。
Clin Cancer Res. 2023 Jun 1;29(11):2066-2074. doi: 10.1158/1078-0432.CCR-22-2765.
4
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.高肿瘤突变负荷的微卫星稳定胃肠道癌的突变分析：一项回顾性队列研究。
Lancet Oncol. 2023 Feb;24(2):151-161. doi: 10.1016/S1470-2045(22)00783-5. Epub 2023 Jan 18.
5
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab.分析局部晚期非小细胞肺癌患者接受放化疗和度伐利尤单抗治疗后的肿瘤突变负担、无进展生存期和局部区域控制情况。
JAMA Netw Open. 2023 Jan 3;6(1):e2249591. doi: 10.1001/jamanetworkopen.2022.49591.
6
Tumor mutational burden and efficacy of chemotherapy in lung cancer.肿瘤突变负荷与肺癌化疗疗效
Clin Transl Oncol. 2023 Jan;25(1):173-184. doi: 10.1007/s12094-022-02924-6. Epub 2022 Aug 22.
7
Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.将肿瘤突变负担和转录组表达整合到预测结肠癌患者免疫检查点抑制剂反应和预后中。
J Physiol Pharmacol. 2022 Apr;73(2). doi: 10.26402/jpp.2022.2.04. Epub 2022 Aug 18.
8
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma.肿瘤突变负荷作为一线免疫检查点抑制剂与卡铂在顺铂不适用于尿路上皮癌患者中的获益预测因子。
JCO Precis Oncol. 2022 Aug;6:e2200121. doi: 10.1200/PO.22.00121.
9
Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer.肿瘤突变负荷是晚期胆道癌患者对免疫检查点抑制剂反应的潜在预测生物标志物。
JCO Precis Oncol. 2022 Jun;6:e2200003. doi: 10.1200/PO.22.00003.
10
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.在 KEYNOTE-062 三期临床试验中，肿瘤突变负荷与帕博利珠单抗联合或不联合化疗作为一线治疗胃癌的疗效相关。
Clin Cancer Res. 2022 Aug 15;28(16):3489-3498. doi: 10.1158/1078-0432.CCR-22-0121.
Zotero 插件